EN

Enovis CorpNYSE ENOV Stock Report

Last reporting period 27 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

2.43

Small

Exchange

XNYS - New York Stock Exchange, Inc

ENOV Stock Analysis

EN

Uncovered

Enovis Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

11/100

Low score

Market cap $B

2.43

Dividend yield

Shares outstanding

54.325 B

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 6,800 full-time employees. The company went IPO on 2008-05-08. The firm is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity solutions that serve the orthopedic reconstructive joint implant market.

View Section: Eyestock Rating